Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.
about
Treatment of Generalized Convulsive Status Epilepticus in Pediatric PatientsHarmonisation of Osmolal Gap - Can We Use a Common Formula?Propylene glycol toxicity in children.Trimethoprim/Sulfamethoxazole-Induced Severe Lactic Acidosis: A Case Report and Review of the Literature.Potential non-hypoxic/ischemic causes of increased cerebral interstitial fluid lactate/pyruvate ratio: a review of available literature.The multifaceted care of status epilepticus.Development and Evaluation of a Guideline for Monitoring Propylene Glycol Toxicity in Pediatric Intensive Care Unit Patients Receiving Continuous Infusion Lorazepam.Status Epilepticus due to Intraperitoneal Injection of Vehicle Containing Propylene Glycol in Sprague Dawley RatsPropylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus.Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.Phenobarbital treatment in a patient with resistant alcohol withdrawal syndrome.Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients.Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity.A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients.Drug-induced hyperlactatemia.
P2860
Q26783899-975D3061-B423-4A76-83D3-B79B19D1940AQ28076857-FC18E88D-BBE9-4DFB-9629-81CE6AC17983Q35124117-F2FDB40A-2C1D-47DD-B88B-AA454E4FB26AQ37206421-6A6D1308-97B5-4618-A05C-A10308166D40Q37845209-978B9B07-638C-4B31-990E-D0B625577E5BQ38133832-660F6BA6-3ED2-4ABD-8D33-4043F14C7673Q38608791-D14FCB5F-93EF-4F46-90CA-717B74E3FD64Q41141704-2E5BAC2E-DFF8-491B-90B1-DBC23A33BE38Q42317057-48A31191-5C66-4B5D-9B35-233637556B4EQ43240250-FC37D7B5-764E-4BA5-96EE-D168D82768DDQ45951132-18564C69-B55A-492D-A7C7-881103BCF61CQ46237705-98B09F34-90A2-46C5-BCA6-3E8970E015D1Q46461320-3345BA4C-1A75-4341-9FCC-206B3C1CE658Q46548480-2466A1AA-6012-47FA-A36F-E3EA91C738A7Q53797180-59DA1023-E6FE-4B11-8579-4C6859DB077B
P2860
Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@en
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@nl
type
label
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@en
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@nl
prefLabel
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@en
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@nl
P2093
P2860
P1433
P1476
Osmol gap as a surrogate marke ...... eiving lorazepam for sedation.
@en
P2093
Andrea R Terrell
Brian J Barnes
Christopher Gerst
Jennifer R Smith
P2860
P356
10.1592/PHCO.2006.26.1.23
P407
P577
2006-01-01T00:00:00Z